Prevention of postoperative adhesion reformation by intermittent intrauterine balloon therapy: a randomised controlled trial

Shi, Xiaoyu; Saravelos, Sotirios H.; Zhou, Qiaozhi; Huang, Xiaowu; Xia, Enlan; Li, Tin‐Chiu

doi:10.1111/1471-0528.15843

Cited by 32 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the healing process, the opposing walls of the uterus adhere together, causing occlusion of the uterine cavity [4,5]. Patients with IUA may experience amenorrhea, dysmenorrhea, irregular menstruation, infertility or repeated abortion [6]. Currently, IUA patients usually undergoes cervical adhesion resection through hysteroscopy and postoperative hormone replacement therapy, but the recurrence rate is as high as 62.5% [7].…”

Section: Introductionmentioning

confidence: 99%

The Effect of Mitomycin C on Reducing Endometrial Fibrosis for Intrauterine Adhesion

et al. 2020

View full text Add to dashboard Cite

Departmental sources Background: Intrauterine adhesion (IUA) is a common reproductive system disease in women, characterized by endometrial stromal cell proliferation, increasing fibroblasts and increasing extracellular matrix secretion. The purpose of this study was to investigate the effect of mitomycin C on reducing endometrial fibrosis for IUA. Material/Methods: Firstly, a rat IUA model was constructed by intrauterine mechanical injury. The endometrial stromal cells and fibroblasts were isolated and treated with mitomycin C. After that, Cell Counting Kit-8 (CCK-8) assay was used to investigate the endometrial stromal cell viability. Furthermore, cell cycle and apoptosis assays of endometrial stromal cells and fibroblasts were performed, respectively. Finally, the cell viability of human endometrial cells or human uterus adhesion fibroblasts treated with mitomycin C was determined using CCK-8 assay with or without estradiol. Results: Endometrial stromal cells were isolated from a rat IUA model. Cell cycle assay results showed that mitomycin C inhibited cell viability and promoted G1 cell cycle arrest and apoptosis in rat IUA endometrial stromal cells. Fibroblasts were also isolated from the rat IUA model. We found that mitomycin C inhibited the synthesis and secretion of collagen type I by western blotting analysis. Furthermore, mitomycin C promoted G1 cell cycle arrest and apoptosis in IUA rat uterine fibroblasts. We found that estradiol decreased the inhibitory effects of cell viability of human endometrial cells and human uterus adhesion fibroblasts by mitomycin C. Conclusions: Our findings revealed that mitomycin C could reduce endometrial fibrosis for intrauterine adhesion.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effect of Mitomycin C on Reducing Endometrial Fibrosis for Intrauterine Adhesion

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the interest of improved patient outcomes, an argument should be made for pooling of cases into dedicated treatment centres. An intra-uterine contraceptive device or a custom-made balloon are traditionally inserted [12][13][14] as a mechanical barrier at completion of a synechiolysis. 15 We choose not to use a true physical barrier.…”

Section: Discussionmentioning

confidence: 99%

Asherman syndrome: Audit of a single‐operator cohort of 423 cases

Vancaillie

Chan

Liu

et al. 2020

Aust NZ J Obst Gynaeco

View full text Add to dashboard Cite

Background The diagnosis of Asherman syndrome, or ‘intra‐uterine adhesions’ is often overlooked when the symptoms of amenorrhea and hematometra are missing. Aims This audit reviews the clinical data of a large cohort of patients treated by a single operator. Materials and Methods From July 1998 till the end of December 2017, 423 patients with intra‐uterine adhesions were treated by a single operator. Clinical information was obtained by review of the medical files and phone interviews. Results Amenorrhea was recorded in 163/423 patients (38.5%), 225/423 (53.2%) patients did not have amenorrhea and for 35/423 (8.3%) patients the information was missing. A hematometra was documented in 19/423 (4.5%) patients. Pregnancy was achieved in 215/246 (87.4%). Patients with stage II disease did best with a pregnancy rate of 94.5% ( P = 0.029). Conclusion Asherman syndrome should be considered in any woman with a history of miscarriage or postpartum curettage who then fails to conceive again.

show abstract

“…Although we are optimistic about the value of the method, well‐designed studies are needed to evaluate its effectiveness and safety. A randomized controlled trial (RCT) completed recently found that intermittent intrauterine balloon therapy can prevent reformation of IUAs after hysteroscopic adhesiolysis. Another RCT from the same group, evaluating the efficacy of intrauterine balloon dilatation therapy in adhesion prevention following hysteroscopic myomectomy, is ongoing.…”

Section: Techniquementioning

confidence: 99%

Ultrasound‐guided repeat intrauterine balloon dilatation for prevention of adhesions

Ludwin

Martins

Ludwin

2019

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Prevention of postoperative adhesion reformation by intermittent intrauterine balloon therapy: a randomised controlled trial

Abstract: Objective To compare the efficacy of intermittent intrauterine balloon dilatation versus standard care in the prevention of adhesion reformation.Design Single-blind randomised controlled trial.

Cited by 32 publications

References 29 publications

The Effect of Mitomycin C on Reducing Endometrial Fibrosis for Intrauterine Adhesion

The Effect of Mitomycin C on Reducing Endometrial Fibrosis for Intrauterine Adhesion

Asherman syndrome: Audit of a single‐operator cohort of 423 cases

Ultrasound‐guided repeat intrauterine balloon dilatation for prevention of adhesions

Contact Info

Product

Resources

About